Anthera Completes Special Protocol Assessment With FDA And Receives EMEA Scientific Advice On Development Path Toward Varespladib Approval Anthera Pharmaceuticals announced they have reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute coronary syndrome (ACS) under the FDA's Special Protocol Assessment procedure.
Source: www.medicalnewstoday.comOptimal Treatment Of Sigmoid Volvulus An article published in the September 28, 2008 issue of the World Journal of Gastroenterology addresses the optimal surgical procedure to treat the age-old illness sigmoid volvulus. Sigmoid volvulus is a bowel obstruction in which a loop of bowel has twisted on itself in an abnormal fashion.
Source: www.medicalnewstoday.comAnadys Pharmaceuticals Announces Successful Outcome Of ANA598 Healthy Volunteer Study And Finalization Of Study Design For Phase Ib Trial In HCV Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary results of a Phase I clinical trial of ANA598 in
healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the
healthy volunteer study, ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported.
Source: www.medicalnewstoday.comRoswell Park Awarded Funds To Study Intra-Operative Staging Of Lung Cancer Chukwumere E. Nwogu, MD, Department of Surgery at Roswell Park Cancer Institute, has been awarded grants from has been awarded grants from the National Cancer Institute and the Thoracic Surgery Foundation totaling nearly $1.2 million to investigate the effectiveness of an intra-operative gamma probe in staging of lung cancer.
Source: www.medicalnewstoday.comDrug Company Gets Into Stem Cell Research Pfizer, the world's largest drug company, is getting into stem cell research to explore the potential of induced pluripotent stem (iPS) cells (where ordinary cells like those taken from adult skin are coaxed into behaving like embryonic stem cells). "These cells will be tremendous in drug discovery," said John McNeish, executive director of Pfizer's global research and development arm in an interview reported by Reuters.
Source: www.medicalnewstoday.comBioView Reports Interim Results Of Early Detection Lung Cancer Diagnostic Test BioView Ltd, (TASE: BIOV) from Rehovot, Israel, reported results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer. In the trial a total of 76 sputum samples were collected from four groups of patients: 1.
Healthy individuals that never smoked 2.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
